Summary
An FDA committee voted against the agency's staff advice to recommend adding two peptides, BP-157 and KPV, to a list allowing specialty pharmacies to dispense them. This move is considered unusual as it bypasses the standard FDA drug approval process, despite concerns from experts about a lack of scientific evidence for the peptides' efficacy and safety.